echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Bronger Ingehandabyl esters prevent and control of children aged 0-18 years VTE was positively evaluated by CHMP

    Bronger Ingehandabyl esters prevent and control of children aged 0-18 years VTE was positively evaluated by CHMP

    • Last Update: 2021-01-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    · To date, no approved therapies have been used to treat and prevent venous thromboembolism in children. Current standard treatments require frequent monitoring of anticoagulants or daily injections. The positive evaluation is based on a dedicated pediatric clinical program for the Dabiga group, including the DIVERSITY study, which complements the clinical evidence profile of safety and efficacy in adults established by the Dabiga group, and recently announced that the European Medicines Agency's Human Medicines Committee (CHMP) has adopted a positive evaluation of the treatment of venous thrombosis events (VTE) and prevention of VTE resuscemia in children under 18 years of age.
    If the submitted adaptation is approved by the European Commission (EC), pediatric patients and medical personnel will be able to use oral anticoagulant therapy, and the risk/benefit profile of the treatment has been fully assessed by health care providers.
    Currently, there are no approved treatments for the treatment or prevention of intravenous blood clots (VCTs) in children, and current standard treatment methods (SOCs) have a number of limitations, including the need to monitor anticoagulant levels frequently or to bear the burden of daily injections.
    positive opinion of CHMP is based on a dedicated paediatric clinical plan.
    clinical study of DIVERSITY showed that in children with a higher risk of VTE, the Dabiga group was not inferior to the standard treatment, and the risk of bleeding was comparable.
    studies have shown that the Dabiga group has good safety outcomes for children with VTE and risk factors for persistent thrombosis.
    based on the results of relevant studies and the likely expansion of the patient population, this much-anticipated approval of the adaptation will be an important milestone for the Dabiga group.
    note: There are deletions in the original text
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.